Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Other Non-Current Liabilities (2018 - 2025)

Ocular Therapeutix (OCUL) has 10 years of Other Non-Current Liabilities data on record, last reported at $887000.0 in Q4 2025.

  • For Q4 2025, Other Non-Current Liabilities fell 93.3% year-over-year to $887000.0; the TTM value through Dec 2025 reached $887000.0, down 93.3%, while the annual FY2025 figure was $887000.0, 93.3% down from the prior year.
  • Other Non-Current Liabilities reached $887000.0 in Q4 2025 per OCUL's latest filing, down from $15.0 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $73.3 million in Q1 2021 and bottomed at $93000.0 in Q4 2022.
  • Average Other Non-Current Liabilities over 5 years is $15.1 million, with a median of $11.7 million recorded in 2022.
  • Peak YoY movement for Other Non-Current Liabilities: crashed 99.54% in 2022, then surged 12688.03% in 2025.
  • A 5-year view of Other Non-Current Liabilities shows it stood at $20.2 million in 2021, then plummeted by 99.54% to $93000.0 in 2022, then grew by 16.13% to $108000.0 in 2023, then surged by 12164.81% to $13.2 million in 2024, then plummeted by 93.3% to $887000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Other Non-Current Liabilities were $887000.0 in Q4 2025, $15.0 million in Q3 2025, and $148000.0 in Q2 2025.